{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T20:11:54Z","timestamp":1790280714755,"version":"4.1.0"},"update-to":[{"DOI":"10.1002\/14651858.cd004289.pub4","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2013,9,11]],"date-time":"2013-09-11T00:00:00Z","timestamp":1378857600000}}],"reference-count":141,"publisher":"Wiley","issue":"5","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd004289.pub5","type":"journal-article","created":{"date-parts":[[2013,9,11]],"date-time":"2013-09-11T11:05:28Z","timestamp":1378897528000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["HMG CoA reductase inhibitors (statins) for dialysis patients"],"prefix":"10.1002","volume":"2014","author":[{"given":"Suetonia C","family":"Palmer","sequence":"first","affiliation":[{"name":"University of Otago Christchurch; Department of Medicine; 2 Riccarton Ave PO Box 4345 Christchurch New Zealand 8140"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sankar D","family":"Navaneethan","sequence":"additional","affiliation":[{"name":"Glickman Urological and Kidney Institute, Cleveland Clinic; Department of Nephrology and Hypertension; Cleveland OH USA 44195"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan C","family":"Craig","sequence":"additional","affiliation":[{"name":"The University of Sydney; Sydney School of Public Health; Edward Ford Building A27 Sydney NSW Australia 2006"},{"name":"The Children's Hospital at Westmead; Cochrane Renal Group, Centre for Kidney Research; Westmead NSW Australia 2145"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David W","family":"Johnson","sequence":"additional","affiliation":[{"name":"Princess Alexandra Hospital; Department of Nephrology; Ipswich Rd Woolloongabba Queensland Australia 4102"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vlado","family":"Perkovic","sequence":"additional","affiliation":[{"name":"The George Institute for Global Health; Renal and Metabolic Division; Camperdown NSW Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sagar U","family":"Nigwekar","sequence":"additional","affiliation":[{"name":"Harvard Medical School; Brigham and Women's Hospital, Massachusetts General Hospital, Scholars in Clinical Sciences Program; Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorgen","family":"Hegbrant","sequence":"additional","affiliation":[{"name":"Diaverum Renal Services Group; Medical Office; PO Box 4167 Lund Sweden SE-227 22"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni FM","family":"Strippoli","sequence":"additional","affiliation":[{"name":"The University of Sydney; Sydney School of Public Health; Edward Ford Building A27 Sydney NSW Australia 2006"},{"name":"The Children's Hospital at Westmead; Cochrane Renal Group, Centre for Kidney Research; Westmead NSW Australia 2145"},{"name":"University of Bari; Department of Emergency and Organ Transplantation; Bari Italy 70100"},{"name":"Mario Negri Sud Consortium; Department of Clinical Pharmacology and Epidemiology; Santa Maria Imbaro Italy"},{"name":"Diaverum; Medical-Scientific Office; Lund Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,9,11]]},"reference":[{"issue":"10","key":"10.1002\/14651858.CD004289.pub5-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1093\/ndt\/gfp260","article-title":"The association between parathyroid hormone and mortality in dialysis patients is modified by wasting","volume":"24","author":"Drechsler","year":"2009","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"24","key":"10.1002\/14651858.CD004289.pub5-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1161\/CIRCULATIONAHA.109.857268","article-title":"Glycemic control and cardiovascular events in diabetic hemodialysis patients","volume":"120","author":"Drechsler","year":"2009","journal-title":"Circulation"},{"issue":"Abstracts Issue","key":"10.1002\/14651858.CD004289.pub5-BIB0003|cit3","first-page":"727A","article-title":"Increasing adiponectin is associated with cardiovascular events and mortality in diabetic patients on hemodialysis [abstract]","volume":"19","author":"Drechsler","year":"2008","journal-title":"Journal of the American Society of Nephrology"},{"issue":"5","key":"10.1002\/14651858.CD004289.pub5-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"874","DOI":"10.2215\/CJN.01170209","article-title":"Antibodies to platelet factor 4-heparin complex and outcome in hemodialysis patients with diabetes","volume":"5","author":"Krane","year":"2010","journal-title":"Clinical Journal of The American Society of Nephrology: CJASN"},{"issue":"2","key":"10.1002\/14651858.CD004289.pub5-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"394","DOI":"10.2215\/CJN.02020408","article-title":"Electrocardiography and outcome in patients with diabetes mellitus on maintenance hemodialysis","volume":"4","author":"Krane","year":"2009","journal-title":"Clinical Journal of The American Society of Nephrology: CJASN"},{"issue":"Abstracts","key":"10.1002\/14651858.CD004289.pub5-BIB0006|cit6","first-page":"22A","article-title":"Impact of dialyzer membrane characteristics on outcome in type 2 diabetic patients on maintenance hemodialysis: results of the 4D study [abstract]","volume":"17","author":"Krane","year":"2006","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Nov","key":"10.1002\/14651858.CD004289.pub5-BIB0007|cit7","first-page":"496A","article-title":"Atorvastatin in Type 2 diabetic patients on hemodialysis (4D-study): baseline characteristics and 1st interim analysis [abstract]","volume":"14","author":"Krane","year":"2003","journal-title":"Journal of the American Society of Nephrology"},{"issue":"5","key":"10.1002\/14651858.CD004289.pub5-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1053\/j.ajkd.2009.06.029","article-title":"Association of LDL cholesterol and inflammation with cardiovascular events and mortality in hemodialysis patients with type 2 diabetes mellitus","volume":"54","author":"Krane","year":"2009","journal-title":"American Journal of Kidney Diseases"},{"issue":"11","key":"10.1002\/14651858.CD004289.pub5-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1038\/ki.2008.484","article-title":"Effect of atorvastatin on inflammation and outcome in patients with type 2 diabetes mellitus on hemodialysis","volume":"74","author":"Krane","year":"2008","journal-title":"Kidney International"},{"issue":"6","key":"10.1002\/14651858.CD004289.pub5-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.2215\/CJN.09121010","article-title":"Atorvastatin and low-density lipoprotein cholesterol in type 2 diabetes mellitus patients on hemodialysis","volume":"6","author":"Marz","year":"2011","journal-title":"Clinical Journal of the American Society of Nephrology: CJASN"},{"issue":"4","key":"10.1002\/14651858.CD004289.pub5-BIB0012|cit11","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1159\/000080241","article-title":"Randomized controlled trial on the efficacy and safety of atorvastatin in patients with type 2 diabetes on hemodialysis (4D study): demographic and baseline characteristics","volume":"27","author":"Wanner","year":"2004","journal-title":"Kidney & Blood Pressure Research"},{"issue":"3","key":"10.1002\/14651858.CD004289.pub5-BIB0011|cit12","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1056\/NEJMoa043545","article-title":"Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis","volume":"353","author":"Wanner","year":"2005","journal-title":"New England Journal of Medicine"},{"issue":"Suppl 71","key":"10.1002\/14651858.CD004289.pub5-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"S222","DOI":"10.1046\/j.1523-1755.1999.07158.x","article-title":"Rationale and design of a trial improving outcome of type 2 diabetics on hemodialysis. Die Deutsche Diabetes Dialyse Studie Investigators","volume":"56","author":"Wanner","year":"1999","journal-title":"Kidney International - Supplement"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD004289.pub5-BIB0014|cit14","first-page":"iv229","article-title":"Effect of lovastatin on high-sensitivity C-reactive protein and hemoglobin in hemodialysis patients [abstract]","volume":"21","author":"Ahmadi","year":"2006","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Suppl","key":"10.1002\/14651858.CD004289.pub5-BIB0015|cit15","first-page":"A283","article-title":"Effect of lovastatin on C-reactive protein and hemoglobin in hemodialysis patients [abstract]","volume":"10","author":"Ahmadi","year":"2005","journal-title":"Nephrology"},{"issue":"Abstracts","key":"10.1002\/14651858.CD004289.pub5-BIB0016|cit16","first-page":"270A","article-title":"Effect of pravastatin on inflammatory status of CAPD patients: a randomized, double-blinded, controlled and cross-over clinical trial [abstract]","volume":"18","author":"Angel","year":"2007","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 6","key":"10.1002\/14651858.CD004289.pub5-BIB0017|cit17","first-page":"vi301","article-title":"Effect of pravastatin on the inflammatory status of CAPD patients: a randomized, double-blinded, controlled and cross-over clinical trial [abstract]","volume":"22","author":"Zuniga","year":"2007","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"13","key":"10.1002\/14651858.CD004289.pub5-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/j.clinbiochem.2008.05.010","article-title":"Effect of fluvastatin on serum prohepcidin levels in patients with end-stage renal disease","volume":"41","author":"Arabul","year":"2008","journal-title":"Clinical Biochemistry"},{"issue":"5","key":"10.1002\/14651858.CD004289.pub5-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1159\/000106803","article-title":"Effect of rosuvastatin on outcomes in chronic haemodialysis patients: baseline data from the AURORA study","volume":"30","author":"Fellstrom","year":"2007","journal-title":"Kidney & Blood Pressure Research"},{"key":"10.1002\/14651858.CD004289.pub5-BIB0020|cit20","first-page":"218a","article-title":"Normalisation of CRP and LDL-C levels is related to reduction of cardiovascular morbidity and mortality in haemodialysis patients on rosuvastatin treatment - a posthoc analysis of the AURORA trial [abstract]","volume":"21","author":"Fellstrom","year":"2010","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD004289.pub5-BIB0021|cit21","unstructured":"Fellstrom B Jardine AG Holdaas H Schmieder R Gottlow M Johnsson E Effect of rosuvastatin versus placebo on cardiovascular outcomes in patients with end-stage renal disease on hemodialysis - results of the Aurora Study [abstract] World Congress of Nephrology; 2009 May 22-26; Milan (Italy) 2009"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD004289.pub5-BIB0022|cit22","first-page":"713","article-title":"A study to evaluate the use of rosuvastatin in subjects on regular haemodialysis: an assessment of survival and cardiovascular events - the AURORA study [abstract]","volume":"18","author":"Fellstrom","year":"2003","journal-title":"Nephrology Dialysis Transplantation"},{"key":"10.1002\/14651858.CD004289.pub5-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1468-6708-6-9","article-title":"Effect of rosuvastatin on outcomes in chronic haemodialysis patients - Design and rationale of the AURORA study","volume":"6","author":"Fellstrom","year":"2005","journal-title":"Current Controlled Trials in Cardiovascular Medicine"},{"issue":"14","key":"10.1002\/14651858.CD004289.pub5-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1056\/NEJMoa0810177","article-title":"Rosuvastatin and cardiovascular events in patients undergoing hemodialysis","volume":"360","author":"Fellstrom","year":"2009","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD004289.pub5-BIB0025|cit25","first-page":"12A","article-title":"Rosuvastatin and LDL cholesterol in diabetic patients receiving hemodialysis - a posthoc analysis of the AURORA trial [abstract]","volume":"21","author":"Holdaas","year":"2010","journal-title":"Journal of the American Society of Nephrology"},{"issue":"7","key":"10.1002\/14651858.CD004289.pub5-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1681\/ASN.2010090987","article-title":"Rosuvastatin in diabetic hemodialysis patients","volume":"22","author":"Holdaas","year":"2011","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD004289.pub5-BIB0027|cit27","unstructured":"Holdaas H Jardine AG Schmieder R Gottlow M Johnsson E Zannad F Effect of rosuvastatin on cardiovascular outcomes in diabetic patients receiving hemodialysis - results from the Aurora Study [abstract] World Congress of Nephrology; 2009 May 22-26; Milan (Italy) 2009"},{"key":"10.1002\/14651858.CD004289.pub5-BIB0028|cit28","unstructured":"Jardine AG Fellstrom B Holdaas H Gottlow M Johnsson E Zannad F Risk factors for cardiovascular events in patients receiving haemodialysis - post hoc analyses of the AURORA study [abstract] World Congress of Nephrology; 2009 May 22-26; Milan (Italy) 2009"},{"issue":"1","key":"10.1002\/14651858.CD004289.pub5-BIB0029|cit29","first-page":"83","article-title":"Rosuvastatin in hemodialysis: short-term effects on lipids and C-reactive protein","volume":"22","author":"Burmeister","year":"2009","journal-title":"Journal of Nephrology"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD004289.pub5-BIB0030|cit30","first-page":"iv472","article-title":"Short-term results of rosuvastatin therapy over lipid profile and hs-C-reactive protein in patients on regular hemodialysis [abstract]","volume":"21","author":"Burmeister","year":"2006","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD004289.pub5-BIB0031|cit31","first-page":"353A","article-title":"Simvastatin decreased high-sensitive c-reactive protein (hs-CRP) and increased serum albumin in hemodialysis (HD) patients [abstract]","volume":"12","author":"Chang","year":"2001","journal-title":"Journal of the American Society of Nephrology"},{"issue":"6","key":"10.1002\/14651858.CD004289.pub5-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1053\/ajkd.2002.33393","article-title":"Effects of simvastatin on high-sensitivity C-reactive protein and serum albumin in hemodialysis patients","volume":"39","author":"Chang","year":"2002","journal-title":"American Journal of Kidney Diseases"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD004289.pub5-BIB0033|cit33","first-page":"191A","article-title":"Vitaestat 1: alpha-tocopherol and atorvastatin in HD- and PD- patients: a short-term, prospective randomised placebo-controlled intervention trial [abstract]","volume":"12","author":"Bilo","year":"2001","journal-title":"Journal of the American Society of Nephrology"},{"issue":"5","key":"10.1002\/14651858.CD004289.pub5-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1111\/j.1365-2796.2005.01484.x","article-title":"Effects of atorvastatin and vitamin E on lipoproteins and oxidative stress in dialysis patients: a randomised-controlled trial","volume":"257","author":"Diepeveen","year":"2005","journal-title":"Journal of Internal Medicine"},{"issue":"6","key":"10.1002\/14651858.CD004289.pub5-BIB0035|cit35","first-page":"A87","article-title":"Vitaestat 1: a prospective randomised placebo controlled trial with a-tocoferol and atorvastatin in patients in hemo- and peritoneal dialysis [abstract]","volume":"16","author":"Diepeveen","year":"2001","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"3","key":"10.1002\/14651858.CD004289.pub5-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1592\/phco.25.3.335.61599","article-title":"Effects of atorvastatin on low-density lipoprotein cholesterol phenotype and C-reactive protein levels in patients undergoing long-term dialysis","volume":"25","author":"Dornbrook-Lavender","year":"2005","journal-title":"Pharmacotherapy"},{"issue":"1","key":"10.1002\/14651858.CD004289.pub5-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1345\/aph.1K407","article-title":"Effects of atorvastatin on Lp(a) and lipoprotein profiles in hemodialysis patients","volume":"42","author":"Joy","year":"2008","journal-title":"Annals of Pharmacotherapy"},{"issue":"Oct","key":"10.1002\/14651858.CD004289.pub5-BIB0038|cit38","first-page":"615A","article-title":"Atorvastatin can safely and effectively improve cholesterol and contemporary measures of cardiovascular risks in hemodialysis patients [abstract]","volume":"15","author":"Joy","year":"2004","journal-title":"Journal of the American Society of Nephrology"},{"issue":"11","key":"10.1002\/14651858.CD004289.pub5-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"3722","DOI":"10.1093\/ndt\/gfr108","article-title":"Combined vascular effects of HMG-CoA reductase inhibitor and angiotensin receptor blocker in non-diabetic patients undergoing peritoneal dialysis","volume":"26","author":"Han","year":"2011","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"4","key":"10.1002\/14651858.CD004289.pub5-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1046\/j.1523-1755.2002.00262.x","article-title":"A placebo controlled trial examining atorvastatin in dyslipidemic patients undergoing CAPD","volume":"61","author":"Harris","year":"2002","journal-title":"Kidney International"},{"issue":"6","key":"10.1002\/14651858.CD004289.pub5-BIB0041|cit41","first-page":"A196","article-title":"A placebo-controlled trial examining the efficacy and safety of atorvastatin in dyslipidaemic patients undergoing CAPD [abstract]","volume":"16","author":"Wheeler","year":"2001","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD004289.pub5-BIB0042|cit42","first-page":"148A","article-title":"Effects of fluvastatin on leg arterial stiffness in hemodialysis patients with type 2 diabetes mellitus [abstract]","volume":"12","author":"Ichihara","year":"2001","journal-title":"Journal of the American Society of Nephrology"},{"issue":"8","key":"10.1002\/14651858.CD004289.pub5-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1093\/ndt\/17.8.1513","article-title":"Fluvastatin prevents development of arterial stiffness in haemodialysis patients with type 2 diabetes mellitus","volume":"17","author":"Ichihara","year":"2002","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD004289.pub5-BIB0044|cit44","first-page":"124","article-title":"Plasma lipids and liporoteins during atorvastatin (ATVS) up-titration in hemodialysis patients with hyperlipidemia: a placebo-controlled study [abstract]","volume":"17","author":"Lins","year":"2002","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"4","key":"10.1002\/14651858.CD004289.pub5-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"287","DOI":"10.5414\/CNP62287","article-title":"Lipid and apoprotein changes during atorvastatin up-titration in hemodialysis patients with hypercholesterolemia: a placebo-controlled study","volume":"62","author":"Lins","year":"2004","journal-title":"Clinical Nephrology"},{"key":"10.1002\/14651858.CD004289.pub5-BIB0046|cit46","unstructured":"Collins JF Robson R MacMahon S Bailey RR PERFECT Study Group Safety and efficacy of enalapril and simvastatin in dialysis patients [abstract] 6th Asian Pacific Congress of Nephrology; 1995 Dec 5-9; Hong Kong 1995 144"},{"issue":"1","key":"10.1002\/14651858.CD004289.pub5-BIB0047|cit47","first-page":"33","article-title":"Effects of simvastatin and enalapril on serum lipoprotein concentrations and left ventricular mass in patients on dialysis","volume":"10","author":"Robson","year":"1997","journal-title":"Journal of Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD004289.pub5-BIB0048|cit48","first-page":"526","article-title":"A randomized controlled trial of simvastatin and enalapril in dialysis patients: effects on serum lipoproteins and left ventricular mass [abstract]","volume":"5","author":"Robson","year":"1994","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD004289.pub5-BIB0049|cit49","unstructured":"Robson RA Collins J Walker RJ MacMahon S A randomised controlled trial of simvastatin and enalapril in dialysis patients: effects on serum lipoproteins and left ventricular mass [abstract] ISN XIII International Congress of Nephrology; 1995 Jul 2-6; Madrid (Spain) 1995 530"},{"key":"10.1002\/14651858.CD004289.pub5-BIB0051|cit50","unstructured":"Walker RJ Sutherland WH Walker H Simvastatin and cholesteryl ester transfer (CET) activity in renal failure (RF) [abstract] ISN XIII International Congress of Nephrology; 1995 Jul 2-6; Madrid (Spain) 1995 529"},{"key":"10.1002\/14651858.CD004289.pub5-BIB0050|cit51","unstructured":"Walker RJ Sutherland WH Walker H Robson RA MacMahon SA The effects of simvastatin and enalapril on plasma cholesteryl ester transfer (CET) activity in renal failure (RF) [abstract] 6th Asian Pacific Congress of Nephrology; 1995 Dec 5-9; Hong Kong 1995 28"},{"issue":"1","key":"10.1002\/14651858.CD004289.pub5-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/ndt\/12.1.87","article-title":"Effect of treatment with simvastatin on serum cholesteryl ester transfer in patients on dialysis. PERFECT Study Collaborative Group","volume":"12","author":"Walker","year":"1997","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"2","key":"10.1002\/14651858.CD004289.pub5-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1053\/ajkd.2002.30547","article-title":"Safety and efficacy of simvastatin in hypercholesterolemic patients undergoing chronic renal dialysis","volume":"39","author":"Saltissi","year":"2002","journal-title":"American Journal of Kidney Diseases"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD004289.pub5-BIB0054|cit54","first-page":"A38","article-title":"Safety and efficacy of simvastatin in hypercholesterolaemic patients undergoing chronic renal dialysis [abstract]","volume":"7","author":"Westhuyzen","year":"2002","journal-title":"Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD004289.pub5-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1053\/ajkd.2002.30547","article-title":"Safety and efficacy of simvastatin in hypercholesterolemic patients undergoing chronic renal dialysis","volume":"39","author":"Saltissi","year":"2002","journal-title":"American Journal of Kidney Diseases"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD004289.pub5-BIB0056|cit56","first-page":"A38","article-title":"Safety and efficacy of simvastatin in hypercholesterolaemic patients undergoing chronic renal dialysis [abstract]","volume":"7","author":"Westhuyzen","year":"2002","journal-title":"Nephrology"},{"key":"10.1002\/14651858.CD004289.pub5-BIB0061|cit57","unstructured":"Study of Heart and Renal Protection (SHARP). Final protocol (Version 5: 12th July 2005) http:\/\/www.ctsu.ox.ac.uk\/\u02dcsharp\/download_protocol_en_v5.pdf"},{"issue":"Suppl 84","key":"10.1002\/14651858.CD004289.pub5-BIB0057|cit58","doi-asserted-by":"crossref","first-page":"S207","DOI":"10.1046\/j.1523-1755.63.s84.4.x","article-title":"Study of Heart and Renal Protection (SHARP)","volume":"63","author":"Baigent","year":"2003","journal-title":"Kidney International - Supplement"},{"issue":"9784","key":"10.1002\/14651858.CD004289.pub5-BIB0058|cit59","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","article-title":"The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial","volume":"377","author":"Baigent","year":"2011","journal-title":"Lancet"},{"issue":"Abstracts Issue","key":"10.1002\/14651858.CD004289.pub5-BIB0059|cit60","first-page":"817A","article-title":"SHARP: an international randomized placebo-controlled trial of lipid-lowering in chronic kidney disease. 1-year safety and efficacy experience [abstract no: SU-PO1044]","volume":"18","author":"SHARP Collaborative Group","year":"2007","journal-title":"Journal of the American Society of Nephrology"},{"issue":"5","key":"10.1002\/14651858.CD004289.pub5-BIB0060|cit61","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.ahj.2010.08.012","article-title":"Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease","volume":"160","author":"Sharp Collaborative Group","year":"2010","journal-title":"American Heart Journal"},{"issue":"1","key":"10.1002\/14651858.CD004289.pub5-BIB0062|cit62","first-page":"29","article-title":"Effect of hydroxymethylglutaryl-CoA reductase inhibitors on low-density lipoprotein cholesterol, interleukin-6, and high-sensitivity C-reactive protein in end-stage renal disease","volume":"5","author":"Soliemani","year":"2011","journal-title":"Iranian journal of Kidney Diseases"},{"issue":"6","key":"10.1002\/14651858.CD004289.pub5-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1080\/00365590510031255","article-title":"Safety and efficacy of atorvastatin in patients with severe renal dysfunction","volume":"39","author":"Holmberg","year":"2005","journal-title":"Scandinavian Journal of Urology & Nephrology"},{"key":"10.1002\/14651858.CD004289.pub5-BIB0065|cit64","unstructured":"Stegmayr BG Brannstrom M Bucht S Dimeny E Ekspong A Granroth B Safety and efficacy of atorvastatin in patients with impaired renal function [abstract] 38th Congress. European Renal Association. European Dialysis and Transplantation Association; 2001 Jun 24-27; Vienna (Austria) 2001 134"},{"issue":"6","key":"10.1002\/14651858.CD004289.pub5-BIB0064|cit65","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1080\/00365590500329304","article-title":"Low-dose atorvastatin in severe chronic kidney disease patients: a randomized, controlled endpoint study","volume":"39","author":"Stegmayr","year":"2005","journal-title":"Scandinavian Journal of Urology & Nephrology"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD004289.pub5-BIB0066|cit66","first-page":"161A","article-title":"Safety and efficacy of atorvastatin in patients with severe renal dysfunction [abstract]","volume":"9","author":"Stegmayr","year":"1998","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD004289.pub5-BIB0067|cit67","first-page":"268A","article-title":"Safety and efficacy of atorvastatin in patients with severe renal dysfunction [abstract]","volume":"10","author":"Stegmayr","year":"1999","journal-title":"Journal of the American Society of Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD004289.pub5-BIB0068|cit68","first-page":"283","article-title":"Atorvastatin at conventional dose did not reduce C-reactive protein in patients on peritoneal dialysis","volume":"21","author":"Tse","year":"2008","journal-title":"Journal of Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD004289.pub5-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1053\/j.ajkd.2004.11.015","article-title":"First United Kingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease","volume":"45","author":"Baigent","year":"2005","journal-title":"American Journal of Kidney Diseases"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD004289.pub5-BIB0070|cit70","first-page":"437A","article-title":"Efficacy and safety of simvastatin and safety of low-dose aspirin among patients with chronic kidney disease: final results of the first UK-heart and renal protection (UK-HARP-I) study [abstract]","volume":"13","author":"Baigent","year":"2002","journal-title":"Journal of the American Society of Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD004289.pub5-BIB0071|cit71","first-page":"238","article-title":"Atorvastatin and simvastatin in patients on hemodialysis: effects on lipoproteins, C-reactive protein and in vivo oxidized LDL","volume":"16","author":"Akker","year":"2003","journal-title":"Journal of Nephrology"},{"key":"10.1002\/14651858.CD004289.pub5-BIB0072|cit72","first-page":"276A","article-title":"Effects of simvastatin on the kinetics of erythrocyte sodium lithium countertransport and C-reactive protein in hemodialysis patients [abstract]","volume":"16","author":"Vareesangthip","year":"2005","journal-title":"Journal of the American Society of Nephrology"},{"issue":"9","key":"10.1002\/14651858.CD004289.pub5-BIB0073|cit73","first-page":"A187","article-title":"Therapeutic effects of simvastatin on hyperlipidemia in uraemic patients on CAPD [abstract]","volume":"12","author":"Velickovic-Radovanovic","year":"1997","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"3","key":"10.1002\/14651858.CD004289.pub5-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1053\/j.ajkd.2003.11.008","article-title":"Does atorvastatin influence serum C-reactive protein levels in patients on long-term hemodialysis?","volume":"43","author":"Vernaglione","year":"2004","journal-title":"American Journal of Kidney Diseases"},{"issue":"Nov","key":"10.1002\/14651858.CD004289.pub5-BIB0075|cit75","first-page":"41A","article-title":"Analysis of the impact of atorvastatin (ATO) on c-reactive protein (CRP) levels in haemodialysis patients (HDP) [abstract]","volume":"14","author":"Vernaglione","year":"2003","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD004289.pub5-BIB0076|cit76","first-page":"712","article-title":"Effects of atorvastatin (ATO) on C-reactive protein (CRP) levels in haemodialysis patients (HDP) : a prospective study [abstract]","volume":"18","author":"Vernaglione","year":"2003","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Suppl 6","key":"10.1002\/14651858.CD004289.pub5-BIB0077|cit77","first-page":"vi322","article-title":"Effects of ezetimibe and ezetimibe plus simvastatin (Vytorin\u00ae) on markers for inflammation and thrombogenesis in end-stage renal disease (ESRD) patients [abstract]","volume":"22","author":"Yu","year":"2007","journal-title":"Nephrology Dialysis Transplantation"},{"key":"10.1002\/14651858.CD004289.pub5-BIB0078|cit78","first-page":"261","article-title":"Lipid-lowering effects of simvastatin and gemfibrozil in CAPD patients: a prospective cross-over study","volume":"12","author":"Akcicek","year":"1996","journal-title":"Advances in Peritoneal Dialysis"},{"key":"10.1002\/14651858.CD004289.pub5-BIB0079|cit79","unstructured":"Bunio A Kwiecinski R Steciwko A Migas A Effect of lipid lowering treatment on direct markers of bone metabolism in hemodialysis patients [abstract] 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15-18; Lisbon (Portugal) 2004 320 1"},{"key":"10.1002\/14651858.CD004289.pub5-BIB0080|cit80","unstructured":"Cappelli P Di Liberato L Del Rosso G Bonomini M Lipid-lowering therapy in patients with chronic renal failure [abstract] 37th Congress. European Renal Association. European Dialysis and Transplantation Association. European Kidney Research Organisation; 2000 Sept 17-20; Nice (France) 2000 181"},{"key":"10.1002\/14651858.CD004289.pub5-BIB0081|cit81","unstructured":"Cheng IKP Li PWC Janus ED Tang CSO Chan TM Lo CY Comparative efficacy of gemfibrozil (G) and simvastatin (S) in the treatment of hyperlipidaemia in renal transplant recipients (RT) - a randomised prospective study [abstract] ISN XIII International Congress of Nephrology; 1995 Jul 2-6; Madrid (Spain) 1995 383"},{"issue":"1 Suppl 2","key":"10.1002\/14651858.CD004289.pub5-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"S48","DOI":"10.1053\/ajkd.2001.20739","article-title":"The CHORUS (Cerivastatin in Heart Outcomes in Renal Disease: Understanding Survival) protocol: a double-blind, placebo-controlled trial in patients with ESRD","volume":"37","author":"Keane","year":"2001","journal-title":"American Journal of Kidney Diseases"},{"issue":"6","key":"10.1002\/14651858.CD004289.pub5-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1053\/j.ajkd.2007.03.003","article-title":"A randomized trial of the effect of statin and fibrate therapy on arterial function in CKD","volume":"49","author":"Dogra","year":"2007","journal-title":"American Journal of Kidney Diseases"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD004289.pub5-BIB0084|cit84","first-page":"A422","article-title":"Effect of statin and fibrate therapy on vascular function in chronic kidney disease (CKD) [abstract]","volume":"10","author":"Dogra","year":"2005","journal-title":"Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD004289.pub5-BIB0085|cit85","first-page":"165","article-title":"Efficacy and safety of simvastatin in the treatment of hyperlipidemia in uremic patients undergoing hemodialysis treatment","volume":"44","author":"Fiorini","year":"1992","journal-title":"Minerva Urologica e Nefrologica"},{"issue":"9","key":"10.1002\/14651858.CD004289.pub5-BIB0086|cit86","first-page":"213","article-title":"Clinical investigation on the hypolipidemic effect of simvastatin versus probucol in hemodialysis patients","volume":"145","author":"Fiorini","year":"1994","journal-title":"Clinica Terapeutica"},{"issue":"5","key":"10.1002\/14651858.CD004289.pub5-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1093\/ndt\/15.5.684","article-title":"Effects of atorvastatin on dyslipidaemia in uraemic patients on peritoneal dialysis","volume":"15","author":"Hufnagel","year":"2000","journal-title":"Nephrology Dialysis Transplantation"},{"key":"10.1002\/14651858.CD004289.pub5-BIB0088|cit88","unstructured":"Khajehdehi A Khajehdehi P Lipid lowering effect of polyunsaturated fatty acids in hemodialysis (HD) patients [abstract] 37th Congress. European Renal Association. European Dialysis and Transplantation Association. European Kidney Research Organisation; 2000 Sept 17-20; Nice (France) 2000 200"},{"key":"10.1002\/14651858.CD004289.pub5-BIB0089|cit89","unstructured":"Kim YJ Lee HK Jeong JU Kim SB Park JS Moon KH Effects of rosuvastatin and gemfibrozil on small dense LDL-cholesterol in chronic hemodialysis (CHD) patients [abstract] World Congress of Nephrology 2009; May 22-26; Milan (Italy) 2009"},{"issue":"1","key":"10.1002\/14651858.CD004289.pub5-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ijcard.2009.05.023","article-title":"A hydroxymethylglutaryl coenzyme A reductase inhibitor improves endothelial function within 7 days in patients with chronic hemodialysis","volume":"145","author":"Kishimoto","year":"2010","journal-title":"International Journal of Cardiology"},{"issue":"3","key":"10.1002\/14651858.CD004289.pub5-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/j.1445-5994.1993.tb01727.x","article-title":"Effect of lovastatin on serum lipid profile in the treatment of dyslipoproteinaemia in uraemic patients on continuous ambulatory peritoneal dialysis","volume":"23","author":"Li","year":"1993","journal-title":"Australian & New Zealand Journal of Medicine"},{"key":"10.1002\/14651858.CD004289.pub5-BIB0092|cit92","first-page":"S428","article-title":"Lovastatin treatment of dyslipoproteinemia in patients on continuous ambulatory peritoneal dialysis","volume":"13 Suppl 2","author":"Li","year":"1993","journal-title":"Peritoneal Dialysis International"},{"issue":"5","key":"10.1002\/14651858.CD004289.pub5-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1093\/ndt\/gfg048","article-title":"Pharmacokinetics of atorvastatin and its metabolites after single and multiple dosing in hypercholesterolaemic haemodialysis patients","volume":"18","author":"Lins","year":"2003","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"6","key":"10.1002\/14651858.CD004289.pub5-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1080\/00365590410033362","article-title":"Study of the quality of information given to patients participating in a clinical trial regarding chronic hemodialysis","volume":"38","author":"Lynoe","year":"2004","journal-title":"Scandinavian Journal of Urology & Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD004289.pub5-BIB0095|cit95","first-page":"111","article-title":"Simvastatin and markers of endothelial function in patients undergoing continuous ambulatory peritoneal dialysis","volume":"24","author":"Malyszko","year":"2002","journal-title":"International Journal of Tissue Reactions"},{"key":"10.1002\/14651858.CD004289.pub5-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1046\/j.1523-1755.1999.07157.x","article-title":"Effect of simvastatin on the lipid profile of hemodialysis patients","volume":"71","author":"Nishikawa","year":"1999","journal-title":"Kidney International - Supplement"},{"issue":"4","key":"10.1002\/14651858.CD004289.pub5-BIB0097|cit97","first-page":"268","article-title":"Reduction of intermediate density lipoprotein by pravastatin in hemo- and peritoneal dialysis patients","volume":"43","author":"Nishizawa","year":"1995","journal-title":"Clinical Nephrology"},{"key":"10.1002\/14651858.CD004289.pub5-BIB0098|cit98","unstructured":"Rincon B Tornero F Uson J Garcia-Carzon A Lozano L Efficacy and side effects of HMG-CoA reductase inhibitors in the treatment of hyperlipemia in hemodialysis patients [abstract] ISN XIII International Congress of Nephrology; 1995 Jul 2-6; Madrid (Spain) 1995 531"},{"issue":"10","key":"10.1002\/14651858.CD004289.pub5-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1038\/sj.ki.5000327","article-title":"Effect of fluvastatin on apolipoprotein-defined lipoprotein subclasses in patients with chronic renal insufficiency","volume":"69","author":"Alaupovic","year":"2006","journal-title":"Kidney International"},{"issue":"1","key":"10.1002\/14651858.CD004289.pub5-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1053\/ajkd.2002.29883","article-title":"Fluvastatin improves lipid abnormalities in patients with moderate to advanced chronic renal insufficiency","volume":"39","author":"Samuelsson","year":"2002","journal-title":"American Journal of Kidney Diseases"},{"key":"10.1002\/14651858.CD004289.pub5-BIB0101|cit101","unstructured":"Sezer M Katirci S Adana S Erturk J Kaya S Simvastatin decreases tumor necrosis factor alpha in patients on peritoneal dialysis [abstract] 41st Congress. European Renal Association. European Dialysis and Transplantation Association; 2004 May 15-18; Lisbon (Portugal) 2004 181"},{"issue":"5","key":"10.1002\/14651858.CD004289.pub5-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1080\/00365590701517244","article-title":"Short-term effect of simvastatin treatment on inflammatory parameters in peritoneal dialysis patients","volume":"41","author":"Sezer","year":"2007","journal-title":"Scandinavian Journal of Urology & Nephrology"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD004289.pub5-BIB0103|cit103","first-page":"217A","article-title":"Effect of simvastatin use on autonomic function in patients with end stage renal disease [abstract]","volume":"13","author":"Singh","year":"2002","journal-title":"Journal of the American Society of Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD004289.pub5-BIB0104|cit104","first-page":"22","article-title":"Favorable effects of long-term low-dose pravastatin administration on lipid metabolism in chronic hemodialysis patients with hypercholesterolemia","volume":"59","author":"Tani","year":"1999","journal-title":"Journal of the Showa Medical Association"},{"issue":"3","key":"10.1002\/14651858.CD004289.pub5-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1053\/j.ajkd.2005.11.018","article-title":"The second United Kingdom Heart and Renal Protection (UK-HARP-II) Study: a randomized controlled study of the biochemical safety and efficacy of adding ezetimibe to simvastatin as initial therapy among patients with CKD","volume":"47","author":"Landray","year":"2006","journal-title":"American Journal of Kidney Diseases"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD004289.pub5-BIB0106|cit106","first-page":"119","article-title":"Biochemical safety and efficacy of co-administration of Ezetimibe and Simvastatin among patients with chronic kidney disease: the second UK-heart and renal protection (UK-HARP-II) study [abstract]","volume":"18","author":"Landray","year":"2003","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"4","key":"10.1002\/14651858.CD004289.pub5-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1038\/ki.1991.92","article-title":"Effects of HMG-CoA reductase inhibitors in hypercholesterolemic patients on hemodialysis","volume":"39","author":"Wanner","year":"1991","journal-title":"Kidney International"},{"issue":"1","key":"10.1002\/14651858.CD004289.pub5-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1159\/000186993","article-title":"Effect of simvastatin on qualitative and quantitative changes of lipoprotein metabolism in CAPD patients","volume":"62","author":"Wanner","year":"1992","journal-title":"Nephron"},{"issue":"6","key":"10.1002\/14651858.CD004289.pub5-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1536\/jhj.45.959","article-title":"Comparison of intermittent with continuous simvastatin treatment in hypercholesterolemic patients with end stage renal failure","volume":"45","author":"Yigit","year":"2004","journal-title":"Japanese Heart Journal"},{"issue":"2","key":"10.1002\/14651858.CD004289.pub5-BIB0110|cit110","first-page":"154","article-title":"Effects of Simvastatin in continuous ambulatory peritoneal dialysis patients with hyperlipidemia","volume":"25","author":"Zhu","year":"2000","journal-title":"Bulletin of Hunan Medical University"},{"issue":"1","key":"10.1002\/14651858.CD004289.pub5-BIB0111|cit111","first-page":"75","article-title":"Clinical protocol. Pravastatin for the prevention of the destruction of the nutritional status of hemodialysis patients exhibiting chronic inflammation","volume":"1","author":"Nardi","year":"2005","journal-title":"Nephrologie et Therapeutique"},{"key":"10.1002\/14651858.CD004289.pub5-BIB0112|cit112","unstructured":"NCT00291863 Simvastatin effect on endothelium dependent venodilation in chronic renal failure patients treated by peritoneal dialysis http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00291863"},{"key":"10.1002\/14651858.CD004289.pub5-BIB0113|cit113","unstructured":"NCT00858637 Efficacy and safety study of MCI-196 versus simvastatin for dyslipidaemia in chronic kidney disease (CKD) subjects on dialysis http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00858637"},{"key":"10.1002\/14651858.CD004289.pub5-BIB0114|cit114","unstructured":"Kang SW The effects of lowering low-density lipoprotein cholesterol levels to new targets on cardiovascular complications in peritoneal dialysis patients http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00999453"},{"key":"10.1002\/14651858.CD004289.pub5-BIB0115|cit115","unstructured":"Australia New Zealand Transplant Registry (ANZDATA) The 32nd Annual Report 2009 Report - Data to 2008 http:\/\/www.anzdata.org.au\/v1\/report_2009.html"},{"issue":"9493","key":"10.1002\/14651858.CD004289.pub5-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins","volume":"366","author":"Baigent","year":"2005","journal-title":"Lancet"},{"issue":"17","key":"10.1002\/14651858.CD004289.pub5-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1001\/jama.295.17.2046","article-title":"Effects of early treatment with statins on short-term clinical outcomes in acute coronary syndromes: a meta-analysis of randomized controlled trials","volume":"295","author":"Briel","year":"2006","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD004289.pub5-BIB0118|cit118","unstructured":"Smith JP Clinical Briefing Document. Endocrinologic and Metabolic Drugs Advisory Committee Meeting. November 2, 2011. New Drug Application 21-687\/S-039:Vytorin (ezetimibe\/simvastatin). New Drug Application 21-445\/S-033:Zetia (ezetimibe) http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/EndocrinologicandMetabolicDrugsAdvisoryCommittee\/UCM277649.pdf"},{"issue":"10","key":"10.1002\/14651858.CD004289.pub5-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1681\/ASN.2007020220","article-title":"End-stage renal disease in the United States: an update from the United States Renal Data System","volume":"18","author":"Foley","year":"2007","journal-title":"Journal of the American Society of Nephrology"},{"issue":"10","key":"10.1002\/14651858.CD004289.pub5-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1681\/ASN.V12102131","article-title":"Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients","volume":"12","author":"Ganesh","year":"2001","journal-title":"Journal of the American Society of Nephrology"},{"issue":"7650","key":"10.1002\/14651858.CD004289.pub5-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"issue":"12","key":"10.1002\/14651858.CD004289.pub5-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJM199809173391203","article-title":"Poor long-term survival after acute myocardial infarction among patients on long-term dialysis","volume":"339","author":"Herzog","year":"1998","journal-title":"New England Journal of Medicine"},{"issue":"6","key":"10.1002\/14651858.CD004289.pub5-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/ki.2011.223","article-title":"Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO)","volume":"80","author":"Herzog","year":"2011","journal-title":"Kidney International"},{"issue":"7414","key":"10.1002\/14651858.CD004289.pub5-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD004289.pub5-BIB0125|cit125","unstructured":"Higgins JP Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"issue":"12","key":"10.1002\/14651858.CD004289.pub5-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1093\/ndt\/12.12.2597","article-title":"Incidence and risk factors of atherosclerotic cardiovascular accidents in predialysis chronic renal failure patients: a prospective study","volume":"12","author":"Jungers","year":"1997","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"6925","key":"10.1002\/14651858.CD004289.pub5-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1136\/bmj.308.6925.367","article-title":"By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease?","volume":"308","author":"Law","year":"1994","journal-title":"BMJ"},{"issue":"2","key":"10.1002\/14651858.CD004289.pub5-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1046\/j.1523-1755.2002.00144.x","article-title":"Hyperhomocysteinemia predicts cardiovascular outcomes in hemodialysis patients","volume":"61","author":"Mallamaci","year":"2002","journal-title":"Kidney International"},{"issue":"2","key":"10.1002\/14651858.CD004289.pub5-BIB0129|cit129","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007784","article-title":"HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis","author":"Navaneethan","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD004289.pub5-BIB0130|cit130","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005019.pub3","article-title":"HMG CoA reductase inhibitors (statins) for kidney transplant recipients","author":"Navaneethan","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD004289.pub5-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"263","DOI":"10.7326\/0003-4819-157-4-201208210-00007","article-title":"Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis","volume":"157","author":"Palmer","year":"2012","journal-title":"Annals of Internal Medicine"},{"issue":"in press","key":"10.1002\/14651858.CD004289.pub5-BIB0132|cit132","article-title":"HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis","author":"Palmer","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"in press","key":"10.1002\/14651858.CD004289.pub5-BIB0133|cit133","article-title":"HMG CoA reductase inhibitors (statins) for kidney transplant recipients","author":"Palmer","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"16","key":"10.1002\/14651858.CD004289.pub5-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1056\/NEJM199010183231606","article-title":"The value of lowering cholesterol after myocardial infarction","volume":"323","author":"Rossouw","year":"1990","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD004289.pub5-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1093\/ndt\/gfn426","article-title":"Risk factors for non-fatal myocardial infarction and cardiac death in incident dialysis patients","volume":"24","author":"Trivedi","year":"2009","journal-title":"Nephrology Dialysis Transplantation"},{"key":"10.1002\/14651858.CD004289.pub5-BIB0136|cit136","unstructured":"United States Renal Data System USRDS 2011 Annual Data Report. National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD http:\/\/www.usrds.org\/2011\/pdf\/v2_ch04_11.pdf"},{"issue":"3","key":"10.1002\/14651858.CD004289.pub5-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1053\/j.ajkd.2006.05.021","article-title":"Cardiovascular outcomes and all-cause mortality: exploring the interaction between CKD and cardiovascular disease","volume":"48","author":"Weiner","year":"2006","journal-title":"American Journal of Kidney Diseases"},{"issue":"3","key":"10.1002\/14651858.CD004289.pub5-BIB0138|cit138","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1053\/j.ajkd.2008.07.037","article-title":"The ABCs of cardioprotection in dialysis patients: a systematic review","volume":"53","author":"Wetmore","year":"2009","journal-title":"American Journal of Kidney Diseases"},{"issue":"3","key":"10.1002\/14651858.CD004289.pub5-BIB0139|cit139","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004289","article-title":"HGM CoA reductase inhibitors (statins) for lowering cholesterol in dialysis patients","author":"Navaneethan","year":"2003","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD004289.pub5-BIB0140|cit140","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004289.pub2","article-title":"HMG CoA reductase inhibitors (statins) for dialysis patients","author":"Navaneethan","year":"2004","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD004289.pub5-BIB0141|cit141","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004289.pub4","article-title":"HMG CoA reductase inhibitors (statins) for dialysis patients","author":"Navaneethan","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD004289.pub5\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,28]],"date-time":"2023-12-28T18:18:45Z","timestamp":1703787525000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD004289.pub5"}},"subtitle":[],"editor":[{"name":"Cochrane Kidney and Transplant Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2013,9,11]]},"references-count":141,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2014,5]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd004289.pub5","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,9,11]]}}}